

AGENDA

**Uniform Formulary Beneficiary Advisory Panel (BAP)
12 July 2018 @ 9:00 AM**

**Naval Heritage Center Theater
701 Pennsylvania Ave., N.W., Washington, DC 20004**

- **Administrative Meeting (BAP members report no later than 7:30 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

Members of the DHA Pharmacy Operations Division (POD) Formulary Management Branch (FMB) will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee (P&T) recommendations for the Uniform Formulary (UF).

The P&T Committee made recommendations for the following drugs/drug classes during the May 2018 meeting:

- **Drug Class Reviews**
 - *Pancreatic Enzyme Replacement Therapy (PERT)*
 - *Growth Stimulating Agents (GSAs)*
 - *Gastrointestinal-2 (GI-2) Agents: Opioid-Induced Constipation (OIC) Subclass*
- **Newly Approved Drugs per 32 CFR 199.21(g)(5)**
 - *apalutamide (Erleada) – Oral Oncologic Agent for Prostate Cancer*
 - *bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) – Antiretrovirals for Human Immunodeficiency Virus (HIV)*
 - *clobetasol propionate 0.025% cream (Impoz) – High Potency Corticosteroids Immune Modulators for Moderate to Severe Plaque Psoriasis*
 - *desmopressin nasal spray (Noctiva) – Miscellaneous Endocrine Agent for nocturia due to nocturnal polyuria*
 - *doxylamine succinate/pyridoxine ER tablets (Bonjesta) – Antiemetic-Antivertigo Agents*
 - *efavirenz/lamivudine/tenofovir disoproxil fumarate (Symfi) – HIV*
 - *efavirenz/lamivudine/tenofovir disoproxil fumarate (Symfi Lo) – HIV*
 - *ertugliflozin (Steglatro) – Non-Insulin Diabetes Drugs – Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitor*
 - *ertugliflozin/sitagliptin (Steglujan) – Non-Insulin Diabetes Drugs –SGLT2 Inhibitor*

- *glycopyrrolate inhalation solution (Lonhala Magnair) – Pulmonary-2: Long-Acting Muscarinic Agents (LAMAs) for Chronic Obstructive Pulmonary Disease (COPD)*
- *ibrutinib tablets (Imbruvica) – Oral Oncologic Agent for mantle cell lymphoma and chronic lymphocytic leukemia, new formulation (note that Imbruvica capsules were already designated as UF prior to the Innovator Rule established in August 2015)*
- *insulin lispro (Admelog) – Short-Acting Insulin for Diabetes Mellitus*
- *lamivudine/tenofovir disoproxil fumarate (Cimduo) – Antiretrovirals for HIV*
- *netarsudil 0.02% ophthalmic solution (Rhopressa) – Glaucoma Agents*
- *pitavastatin magnesium (Zypitamag) – Antilipidemic-Is (LIP-Is)*
- *secnidazole (Solosec) – Miscellaneous Anti-Infective for bacterial vaginosis in adult women*
- *tezacaftor/ivacaftor (Symdeko) – Cystic Fibrosis Agents*
- *vancomycin oral solution (Firvanq) – Gastrointestinal-2 agents: Miscellaneous for Clostridium difficile associated diarrhea or enterocolitis*
- **Utilization Management Issues**
 - *Prior Authorization Criteria—Updated Criteria*
 - *Antiemetic-Antivertigo Agents: doxylamine succinate and pyridoxine hydrochloride ER (Diclegis)*
 - *Targeted Immunomodulatory Biologics (TIBs): abatacept (Orencia), secukinumab (Cosentyx), and apremilast (Otezla)*
 - *Oncological Agents: abiraterone acetate (Zytiga) and abemaciclib (Verzenio)*
 - *Non-Insulin Diabetes Drugs: Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs)/Insulin Combination: insulin glargine/lixisenatide (Xultophy) and insulin degludec/liraglutide (Soliqua)*
 - *Parkinson’s Disease Drugs: amantadine hydrochloride extended release (Gocovri)*
- **National Defense Authorization Act (NDAA) 2008, Section 703 Actions**
- **Panel Discussions**

The UF BAP will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendations and vote to accept or reject them. The Panel will provide comments on their vote as directed by the Panel Chairman.